Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes

Vaccine

Volumn 20, Issue 13-14, 2002, Pages 1741-1753

  Iosef, Cristiana ^a   Van Nguyen, Trang ^a   Jeong, Kwang Il ^a   Bengtsson, Karin ^b   Morein, Bror ^b   Kim, Yunjeong ^a   Chang, Kyeong Ok ^a   Azevedo, Marli S P ^a   Yuan, Lijuan ^c   Nielsen, Paul ^a   Saif, Linda J ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Immunostimulating complexes (ISCOMs); Rotavirus; Virus like particle (VLP) vaccine

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; ISCOM; RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGENICITY; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GNOTOBIOTICS; HUMAN ROTAVIRUS; IMMUNE ADHERENCE; IMMUNIZATION; IMMUNOSTIMULATION; INTESTINE CELL; LYMPHOID TISSUE; NONHUMAN; PRIORITY JOURNAL; ROTAVIRUS; SWINE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS ATTENUATION; VIRUS INFECTION; VIRUS PARTICLE; VIRUS VIRULENCE;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-PRODUCING CELLS; GERM-FREE LIFE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTESTINES; ISCOMS; LYMPHOID TISSUE; ROTAVIRUS; SWINE; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0037086488     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00031-2     Document Type: Article

References (43)

1. Review of rotavirus vaccine trials in Finland
2. Symptoms associated with Rhesus-human reassortant rotavirus vaccine in infants
3. Intussusception among infants given an oral rotavirus vaccine
4. The requirement of lipids for the formation of immunostimulating complexes (ISCOMs)
5. The serum antibody response distributed in subclass and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes
6. The immunostimulating complexes (ISCOM) is an efficient mucosal delivery system for respiratory syncitial virus (RSV) envelope antigens inducing local and systemic antibody responses
7. Induction of Th1- and Th2-CD4 T-cell responses by oral or parenteral immunizaion with ISCOMs
8. Quillaja saponin formulations that stimulated proinflammatory cytokines elicit a potent acquired cell-mediated immunity
9. Immunomodulation by ISCOMs, immuno-stimulating complexes
10. Augmentation of human influenza A virus-specific cytotoxic T-lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMs)
11. Monocyte and ISCOM enhancement of cell-mediated response to cytomegalovirus
12. Measles virus fusion protein presented in an immune-stimulating complex (ISCOM) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus specific T-cells and protection in mice
13. Beta-chemokines and neutralizing antibody titres correlate with heterologous protection of HIV-1 vaccinated macaques
14. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T-lymphocytes in vivo and are immunogenic by the oral route
15. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigen
16. Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21
17. Effect of oral rotavirus/ISCOM vaccines on immune responses in gnotobiotic lambs
18. The gnotobiotic pig as a model for studies of disease pathogenesis and immunity to rotavirus
19. Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs
20. Pathogenesis of an attenuated and virulent strain of group A human rotavirus on neonatal gnotobiotic pigs
21. Active protection against rotavirus infection of mice following intraperitoneal immunization
22. Protective immunity induced by oral immunization with rotavirus DNA vaccine encapsulated in microparticles
23. Protective immunity induced by rotavirus DNA vaccines
24. Systemic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease
25. Antibody-secreting cell responses and protective immunity assessed in gnotobiotic pigs inoculated orally or intramuscularly with inactivated human rotavirus
26. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular with inactivated rotavirus
27. Expression of rotavirus VP2 produces empty core-like particles
28. Heterotypic production and induction of a broad heterotypic neutralization response by rotavirus-like particles
29. Vaccine adjuvants: Preparation methods and study protocols
30. Isotype-specific antibody-secreting cells to transmissible gastroenteritis virus and porcine respiratory coronavirus in gut- and bronchus-associated lymphoid tissues of sucking pigs
31. Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and ISCOMS
32. Immune responses to ISCOM® formulations in animal and primate models
33. Adjuvant activity of non-toxic Quillaja saponaria molina components for use in ISCOM matrix
34. ISCOMS containing purified Quillaja saponins upregulate both Th1- and Th2-like immune responses
35. Intranasal administration of 2/6-rotavirus-like-particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody secreting cell responses but not protective immunity in gnotobiotic pigs
36. Rotavirus 2/6-virus like-particles administrated intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge
37. Inhibition of T-cell response by Escherichia coli heat-labile enterotoxin-treated epithelial cells
38. Inhibition of class II major histocompatibility complex antigen processing by Escherichia coli heat-labile enterotoxin requires an enzimatically active A subunit
39. Vaccination against Helicobacter pylori in non-human primate models and humans
40. Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus
41. Immune responses to individual rotavirus proteins following heterologous and homologous rotavirus infection in mice
42. Viral enteric diseases